Division of Hematopathology, Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY, USA.
Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA.
Mod Pathol. 2020 Jul;33(7):1380-1388. doi: 10.1038/s41379-020-0498-z. Epub 2020 Feb 12.
Ancillary testing during the initial workup of acute myeloid leukemia (AML) is largely performed using aspirated materials. We utilized multiplex immunofluorescence (MIF) imaging with digital image analysis to perform an in situ analysis of the microenvironment in NPM1-mutated AML using diagnostic bone marrow biopsy tissues (N = 17) and correlated these findings with diagnostic next-generation sequencing (NGS, N = 17), flow cytometry (FC, N = 14), and first remission (CR1) NPM1-specific molecular MRD (n = 16) data. The total CD3-positive T-cell percentages correlated positively between FC and MIF (r = 0.53, p = 0.05), but were significantly lower by MIF (1.62% vs. 3.4%, p = 0.009). The percentage of mutant NPM1-positive (NPM1c+) cells ranged from 9.7 to 90.8% (median 45.4%) and did not correlate with the NPM1 mutant allele fraction by NGS (p > 0.05). The percentage of CD34+/NPM1c+ cells ranged from 0 to 1.8% (median 0.07%). The percentage of NPM1c+ cells correlated inversely (34% vs. 62%, p = 0.03), while the percentages of CD3-/NPM1c- cells (64% vs. 35%, p = 0.03), and specifically CD3-/CD4-/NPM1c- cells (26% vs. 13%, p = 0.04), correlated positively with subsequent MRD. Discordances between MIF and FC/NGS data suggest that aspirate materials are likely an imperfect reflection of the core biopsy tissue. Furthermore, increased numbers of NPM1 wild-type cells within the microenvironment at diagnosis correlate with the subsequent presence of MRD.
在急性髓系白血病 (AML) 的初始检查中,辅助检测主要使用抽吸材料进行。我们利用多重免疫荧光 (MIF) 成像和数字图像分析,对 NPM1 突变型 AML 的微环境进行原位分析,使用诊断性骨髓活检组织 (N=17),并将这些发现与诊断性下一代测序 (NGS,N=17)、流式细胞术 (FC,N=14) 和首次缓解 (CR1) NPM1 特异性分子微小残留病 (MRD,n=16) 数据相关联。FC 和 MIF 之间的总 CD3 阳性 T 细胞百分比呈正相关 (r=0.53,p=0.05),但 MIF 检测值明显更低 (1.62% vs. 3.4%,p=0.009)。突变型 NPM1 阳性 (NPM1c+) 细胞的百分比范围为 9.7%至 90.8% (中位数为 45.4%),与 NGS 检测的 NPM1 突变等位基因分数无关 (p>0.05)。CD34+/NPM1c+细胞的百分比范围为 0 至 1.8% (中位数为 0.07%)。NPM1c+细胞的百分比呈负相关 (34% vs. 62%,p=0.03),而 CD3-/NPM1c-细胞 (64% vs. 35%,p=0.03),特别是 CD3-/CD4-/NPM1c-细胞 (26% vs. 13%,p=0.04) 的百分比与随后的 MRD 呈正相关。MIF 和 FC/NGS 数据之间的差异表明,抽吸材料可能无法完美反映核心活检组织。此外,诊断时微环境中 NPM1 野生型细胞数量的增加与随后存在 MRD 相关。